Sorcero, a provider of AI-powered solutions for the life sciences industry, announced on Tuesday its acquisition of Axiom Health, a real-world data platform focused on the medical technology industry.
Following the acquisition, the Axiom Health platform becomes Sorcero MedTech, enabling the Sorcero Intelligence Platform to become the first unified AI platform for both pharmaceutical and medical device organisations, addressing the growing demand for real-time insights across healthcare.
By integrating the former Axiom Health MedTech industry data lake with The Sorcero Intelligence Platform, Sorcero claims that it will now provide life sciences organisations with broader visibility into new market opportunities and improved patient outcomes.
Sorcero's acquisition also extends its reach into the global MedTech market, which is valued at USD595bn according to Medical Product Outsourcing.
The enhanced platform enables: cross-vertical analysis spanning pharma, medical device, and stakeholder data; rapid AI-powered insights on product development and commercialisation; complete understanding of the patient journey; stakeholder micro-targeting to understand exactly why, how, and when their product is being used, across medical devices and pharmaceutical portfolios; and enhanced market intelligence for targeted decision-making and commercial strategy.
The transaction was supported by a new investment from First Trust Capital Partners LLC and other Axiom investors.
Saluda Medical secures CE certification for EVA Sensing Technology in Europe
Antin to acquire clinical trial equipment provider Emsere
Hyphens Pharma licenses Cerapro skin cream to Louis Widmer for six European markets
Profusa signs French distributor to expand Lumee Oxygen rollout in Europe
Sensiva Health names new chief operating officer
BrioHealth Solutions enrols 100th participant in BrioVAD System trial
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
BioCryst wins FDA approval for oral HAE prophylaxis in young children
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Galderma secures EU MDR certification for Sculptra, expanding use to multiple body areas
Clinical Laserthermia Systems applies for CE marking of ClearPoint Prism neuro laser system